https://www.thebodypro.com/category/managing-hiv-drug-resistance-pro/tag/conference-coverage
Managing HIV Drug Resistance

Conference Coverage

The Latest

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options Img

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options

A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...

Pre-ART Drug Resistance in Rural South Africa but Limited Clinical Impact With Good Adherence Img

Pre-ART Drug Resistance in Rural South Africa but Limited Clinical Impact With Good Adherence

The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.

HIV Researchers Reassert Treatment Is Prevention Img

HIV Researchers Reassert Treatment Is Prevention

"We need to meet people where they are at. If you do not want to have a medical provider, but you are interested in being on [pre-exposure prophylaxis], then we should create an environment where it is possible for you to get that," says Matthew Gold...

Assessing Benefits of Pre-Exposure Prophylaxis Relative to Risks of Drug Resistance Img

Assessing Benefits of Pre-Exposure Prophylaxis Relative to Risks of Drug Resistance

"Resistant infections during PrEP [pre-exposure prophylaxis] should be weighed against the numbers of infections averted," stated renowned HIV prevention and PrEP (pre-exposure prophylaxis) researcher Robert Grant, M.D., M.P.H., during a PrEP-focused...

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial Img

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial

Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.

zero

Zero: No Linked HIV Transmissions in PARTNER Study After Couples Had Sex 58,000 Times Without Condoms

The PARTNER study provides the strongest estimate of actual risk of HIV transmission when an HIV positive person has undetectable viral load -- and that this risk is effectively zero.

Insight Into HIV Transmission Risk When the Viral Load Is Undetectable and No Condom Is Used Img

Insight Into HIV Transmission Risk When the Viral Load Is Undetectable and No Condom Is Used

If a major study found "zero" cases of HIV transmission among mixed-status couples, why did it also find that the risk was higher than zero?

Promo Image

NNRTI Resistance Found in 12% of People Stopping Treatment With Undetectable Viral Load: Implications for Stock-Outs

Although stopping ART is not recommended, this still occurs due to drug stock-outs in some countries and retrospective data from the UK HIV Drug Resistance Database (HDRD) highlighted the risk this has for developing drug resistance.

Valentina Cambi...

Promo Image

Even HIV-Infected Men With Undetectable HIV in Blood May Shed HIV in Semen

HIV-infected men on antiretroviral therapy sometimes still shed HIV RNA in their semen even if they have suppressed levels of HIV RNA in their blood plasma and no symptoms of other sexually transmitted diseases, according to the first-ever longitudin...